Why the study?
HTN is a major risk factor for AF, and although RDN shows promise as an innovative intervention in AF treatment, its efficacy and long-term results remain the focus of ongoing investigation.
Does renal artery denervation improve outcomes in patients with atrial fibrillation?
Does renal artery denervation improve outcomes in patients with atrial fibrillation?
This review highlights the potential of renal artery denervation as an emerging therapy for atrial fibrillation, emphasizing the need for further long-term efficacy studies.
Answers are grounded in this paper and cite their sources.
Renal denervation should not change AF practice; leaves open efficacy for prospective randomized trials.
Renal denervation (RDN) is a minimally invasive procedure by which ultrasound guided ablation or radiofrequency ablation is used to target sympathetic nerves within the walls of renal arteries causing a decrease in their activity and consequently, a reduction in the patient’s blood pressure. Although RDN has emerged as a novel therapy for the treatment of resistant hypertension (HTN), its indication spectrum and new therapeutic options are still broadening. HTN remains the main risk factor for the development and maintenance of many cardiovascular diseases including AF. Therefore, initial findings suggest that renal artery ablation proposes to be an innovative intervention in the treatment of AF through the precise targeting of efferent sympathetic and afferent sensory renal nerve signaling, selectively ablating the renal sympathetic nerves. Nevertheless, the efficacy and long-term results of RDN continues to be the focus of ongoing investigation and exploration.
No takes yet. Share an insight, caveat, or question.
Shudayfat et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: